Shares of Humana Inc. (NYSE:HUM – Get Free Report) were down 9.1% on Wednesday. The stock traded as low as $409.25 and last traded at $403.12. Approximately 605,237 shares were traded during trading, a decline of 63% from the average session volume of 1,647,300 shares. The stock had previously closed at $443.34.
Recent Humana Headlines
Here are a few of the latest headlines about HUM:
- Positive Sentiment: Royal Bank of Canada upgraded Humana to “Outperform,” adding to a generally favorable analyst backdrop. Article: Royal Bank of Canada Upgrades Humana to Outperform
- Positive Sentiment: Humana recently raised its 2026 adjusted EPS outlook to at least $9.50. Its new national “Gold Card” program, intended to reduce prior-authorization requirements for some providers, may also improve administrative efficiency. Article: Humana to Launch National Gold Card Program
- Negative Sentiment: The main pressure is CMS’s proposed CRUSH rule, which would strengthen Medicare Advantage risk-adjustment audits and allow broader recovery of unsupported payments through extrapolation. CMS estimates the measure could generate about $9 billion in collections per payment year; Humana’s exposure is significant given its large Medicare Advantage membership. The proposal is not final, but it raises concerns about potential liabilities and tighter oversight. Article: Medicare Advantage audit proposal pressures insurers
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. Wells Fargo & Company lowered shares of Humana from an “overweight” rating to a “strong sell” rating in a research note on Monday. Wall Street Zen raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, November 9th. KeyCorp downgraded shares of Humana from an “overweight” rating to a “sector weight” rating in a research report on Monday. Robert W. Baird raised Humana from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $390.00 to $596.00 in a research note on Friday, October 9th. Finally, Truist Financial lifted their price target on shares of Humana from $415.00 to $475.00 and gave the stock a “hold” rating in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $484.78.
Humana Price Performance
The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65. The firm has a fifty day simple moving average of $410.55 and a two-hundred day simple moving average of $319.48. The firm has a market cap of $47.69 billion, a PE ratio of 38.71, a PEG ratio of 2.20 and a beta of 0.65.
Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.30. The company had revenue of $41.16 billion during the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm’s revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. Equities analysts predict that Humana Inc. will post 9.66 EPS for the current fiscal year.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be issued a $0.8850 dividend. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.9%. Humana’s dividend payout ratio is currently 34.44%.
Insiders Place Their Bets
In related news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the transaction, the insider directly owned 21,910 shares in the company, valued at approximately $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Hedge Funds Weigh In On Humana
Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Humana in the second quarter valued at approximately $4,138,160,000. State Street Corp increased its position in shares of Humana by 1.6% during the third quarter. State Street Corp now owns 5,543,942 shares of the insurance provider’s stock worth $2,115,402,000 after acquiring an additional 86,870 shares during the last quarter. Pzena Investment Management LLC purchased a new position in shares of Humana during the 2nd quarter valued at approximately $1,749,014,000. Assenagon Asset Management S.A. raised its stake in shares of Humana by 20,126.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after purchasing an additional 1,249,272 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Humana in the 2nd quarter worth approximately $329,760,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Read More
- Five stocks we like better than Humana
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
